Nurix Therapeutics, Inc. NRIX Return on equity

Return on equity at other companies

ArvinasARVN

-42.3%-53.5pp

Kymera TherapeuticsKYMR

-24.2%-5.2pp

Monte Rosa Therapeutics, Inc.GLUE

-42.7%—

Septerna, Inc.SEPN

-12.2%—

Stoke Therapeutics, Inc.STOK

-45.6%-66.1pp

RegenxbioRGNX

-137.6%-817pp

FAQ

What is Nurix Therapeutics, Inc.'s return on equity?

Nurix Therapeutics, Inc. (NRIX) reported return on equity of -80.3% in Q1 2026.

How has Nurix Therapeutics, Inc.'s return on equity changed year-over-year?

Nurix Therapeutics, Inc.'s return on equity decreased by 58.5% year-over-year, from -50.7% to -80.3%.

What is the long-term trend for Nurix Therapeutics, Inc.'s return on equity?

Over 4 years (2021 to 2025), Nurix Therapeutics, Inc.'s return on equity has grown at a 7.6% compound annual growth rate (CAGR), from -37.1% to -49.6%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.